CN1193091C - Serumless medium suitable for growth and maintenance of young hamster kidney cell - Google Patents
Serumless medium suitable for growth and maintenance of young hamster kidney cell Download PDFInfo
- Publication number
- CN1193091C CN1193091C CNB021106444A CN02110644A CN1193091C CN 1193091 C CN1193091 C CN 1193091C CN B021106444 A CNB021106444 A CN B021106444A CN 02110644 A CN02110644 A CN 02110644A CN 1193091 C CN1193091 C CN 1193091C
- Authority
- CN
- China
- Prior art keywords
- acid
- growth
- cell
- serum
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000699800 Cricetinae Species 0.000 title claims abstract description 8
- 230000012010 growth Effects 0.000 title claims abstract description 8
- 238000012423 maintenance Methods 0.000 title claims abstract 3
- 210000003292 kidney cell Anatomy 0.000 title claims description 5
- 239000012679 serum free medium Substances 0.000 claims abstract description 13
- 239000002609 medium Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930195722 L-methionine Natural products 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 3
- 101710134784 Agnoprotein Proteins 0.000 claims description 3
- 235000019743 Choline chloride Nutrition 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 229960003178 choline chloride Drugs 0.000 claims description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003136 leucine Drugs 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 235000019136 lipoic acid Nutrition 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 229960005190 phenylalanine Drugs 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 2
- 235000021360 Myristic acid Nutrition 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- 235000019766 L-Lysine Nutrition 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 229930182816 L-glutamine Natural products 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229960003767 alanine Drugs 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 239000007640 basal medium Substances 0.000 claims 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- 229940054269 sodium pyruvate Drugs 0.000 claims 1
- 235000019157 thiamine Nutrition 0.000 claims 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- 239000011721 thiamine Substances 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000011726 vitamin B6 Substances 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 13
- 230000010261 cell growth Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000002070 Transferrins Human genes 0.000 description 4
- 108010015865 Transferrins Proteins 0.000 description 4
- 150000002505 iron Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 229910002554 Fe(NO3)3·9H2O Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229910018143 SeO3 Inorganic materials 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- -1 iron ion Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开一种适于幼仓鼠肾(BHK)细胞高密度生长和维持的低蛋白无血清培养基,该培养基具有蛋白含量低、易于分离纯化及适于工业化生产的特点。The invention discloses a low-protein serum-free medium suitable for high-density growth and maintenance of baby hamster kidney (BHK) cells. The medium has the characteristics of low protein content, easy separation and purification, and is suitable for industrial production.
Description
Technical field
The present invention relates to a kind of low albumen serum free medium that is suitable for the baby hamster kidney cell high-density growth and keeps.
Background technology
Young hamster kidney (BHK) cell is a kind of mammal cell line that can infinitely go down to posterity, and has been widely used in producing biological technology products such as vaccine, diagnostic reagent and medicine.
Bhk cell is cultivated in blood serum medium is arranged usually, but that the interpolation of serum exists is many unfavorable: the first, and serum is very expensive, and the expense of serum accounts for more than 50% of substratum total expenses, causes production cost to increase substantially; The second, the difference of serum quality can influence the cell growth between criticizing and criticizing, and finally influences quality product; The 3rd, serum is easily by mycoplasma and external reagent contamination; The 4th, serum protein has increased that the downstream cultured products is separated, the difficulty of purifying, and these shortcomings make the use of serum in cell large scale is cultivated be restricted, and cause people to launch the development and application research of serum free medium.
In recent years, the research and development development of serum free medium is very fast, reported the multiple serum-free culture that can support the growth of different sorts cell, Casser et al. (In Vitro Cell.Devel.Biol. for example, 88,21:588 1985) developed a kind of substratum that can support Chinese hamster ovary celI growth.This substratum has added Transferrins,iron complexes, Regular Insulin and Sodium Selenite based on DMEM/F12 (1: 1), (the serum free medium basic components of basic medium+ITS) that Here it is now is widely adopted.United States Patent (USP) U.S.592107 discloses a kind of serum free medium, and this substratum contains high-level amino acid, and has added different somatomedins and trace element, can support Chinese hamster ovary celI high-density suspension culture.But these substratum are limited to hybridoma more and Chinese hamster ovary celI is cultivated, and general protein content is still higher, can reach tens milligrams usually to several grams, cause the difficulty of downstream product separation and purification and cost to increase.Do not appear in the newspapers and relate to the low albumen serum free medium that is suitable for the baby hamster kidney cell long-term cultivation.
Summary of the invention
The present invention discloses a kind of young hamster kidney (BHK) cell high-density growth and low albumen serum free medium of keeping of being suitable for, this substratum have protein content low, be easy to separation and purification and be suitable for the characteristics of suitability for industrialized production.
Design of the present invention:
The recruitment factor kind of alternative serum is a lot, generally includes some human necessary somatomedins, hormone, lipid, conjugated protein and various trace elements etc.For effective alternative serum, the high-density growth of sustenticular cell, the present invention has added following composition on the basis of basic medium DMEM:
(1) Transferrins,iron complexes: a kind of glycoprotein in conjunction with iron, with the single-minded receptor acting of cell surface, transmit iron ion.
(2) Regular Insulin: beta Cell of islet excretory polypeptide hormone can promote the cell growth.
(3) VITAMIN: the moiety of cell is the essential material of cell growth institute, and cell self can't synthesize, and must absorb from the external world.
(4) trace element: as Cu, Fe, Zn, Se, Co, Mo, Sn, Si, V, Mn etc. mainly play the cell physiological process and regulate.
(5) beta-mercaptoethanol: promote the absorption of Gelucystine, can make gsh be in reduced state, thereby the protection cell is avoided the infringement of hydrogen peroxide.
(6) lipid: comprise some lipid acid and lipoid, can promote the cell growth.For example: linolic acid, linolenic acid, oleic acid and cholesterol etc.
Technical scheme of the present invention:
Substratum of the present invention is a kind of composition, forms (unit of additive capacity is mg/L if no special instructions) by basic medium DMEM and following additive:
L-aspartic acid 0-20
L-L-glutamic acid 10-40
Altheine 20-50
L-Serine 0-10
L-glutaminate 0-200
L-Histidine 0-40
L-L-Ala 0-40
L-arginine 50-150
L-methionine(Met) 10-50
L-tryptophane 0-50
L-phenylalanine 10-60
L-leucine 20-60
L-Methionin 40-100
L-proline(Pro) 10-30
NH
4VO
3 0.02-0.1
SnCl
22H
2O 1.00-2.00
Ba(C
2H
3O
2)
2 0.01-0.05
AgNO
3 0.01-0.05
AlCl
36H
2O 0.3-1.5
3CdSO
48H
2O 0.001-0.005
CoCl
26H
2O 0.03-0.15
(NH
4)
6MoO
244H
2O 0.01-0.05
NiCl
26H
2O 0.1-0.5
Na
2SeO
3 0.01-0.05
KBr 0-0.0002
NaF 0-0.005
KI 0-0.0005
Na
2SiO
3 0.01-0.05
NaH
2PO
32H
2O 0-100
FeSO
47H
2O 0.3-1.5
CuSO
45H
2O 0.001-0.005
ZnSO
4 0.3-1.5
HEPES 1000-2500
Regular Insulin 2-20
Transferrins,iron complexes 2-20
Sodium.alpha.-ketopropionate 0-150
Primatone 1000-2500
Lipid mixture * 0.1%-0.5% (v/v)
Reduced glutathion 0.3-1.5
Vitamins C 3.5-13.5
Vitamins B
60-0.06
Vitamins B
120-0.68
Choline chloride 60 0-5
Inositol 0-5
Vitamin H (Biotin) 0-0.02
Niacinamide 0-2.02
Riboflavin 0-0.044
VitB1 0-2.17
Xanthoglobulin 0-2
Thioctic Acid 0-0.1
Beta-mercaptoethanol 0-2.5
*: the chemical ingredients of producing for GIBCO determine the lipid concentrated solution (attached composition, mg/L)
Arachidonic acid 2
Cholesterol 220
DL-alpha-tocopherol acetate 70
Linolic acid 10
Linolenic acid 10
Myristic acid 10
Oleic acid 10
Palm diluted acid 10
Palmitinic acid 10
Pluronic?F-68 100000
Stearic acid 10
Tween 80 2200
The above all substances is the commercial goods.
Substratum of the present invention adopts conventional method formulated.
Substratum using method of the present invention is an ordinary method.
Description of drawings
Fig. 1 is the test-results diagram of embodiment 1 and Comparative Examples.
Wherein:
●-the adopt cell density (* 10 of serum free medium
5Cells/mL)
▲-the adopt cell density (* 10 that blood serum medium is arranged
5Cells/mL)
Specific implementation method
Below will the present invention is further illustrated by embodiment.
Embodiment 1
(comprise basic medium DMEM composition, mg/L) insert bhk cell (seed cell is the serum-free culture cell) then in this substratum, inoculum density is 1.4 * 10 according to following concentration preparation serum free medium
5Cells/mL, cultivate 4 days (96 hours) after, cell density can reach 1.4 * 10
6Cells/mL.
First part: amino acid
L-Gelucystine two hydrochloric acid 63
L-aspartic acid 8
L-L-glutamic acid 19
Altheine 31
Glycine 30
L-Serine 44
L-glutaminate 688
L-Histidine 63
L-L-Ala 12
L-arginine 190
L-methionine(Met) 48
L-tryptophane 28
L-phenylalanine 86
Two water L-tyrosine disodiums 104
L-leucine 147
L-Isoleucine 105
L-Methionin 209
L-proline(Pro) 17
L-Threonine 95
L-Xie Ansuan 94
The second section trace element
CaCl
2 200
Fe(NO
3)
3·9H
2O 0.1
KCl 400
NCl 6400
NaHCO
3 3700
NH
4VO
3 0.092
SnCl
22H
2O 1.556
Ba(C
2H
3O
2)
2 0.02
AgNO
3 0.02
AlCl
3·6H
2O 0.99
3CdSO
4·8H
2O 0.003
CoCl
2·6H
2O 0.101
MnSO
4·H
2O 97.67
(NH
4)
6MoO
24·4H
2?O 0.033
NiCl
2·6H
2O 0.35
Na
2SeO3 0.01
KBr 0.0001
NaF 0.0042
KI 0.0002
Na
2SiO
3 0.01
NaH
2PO
3·2H
2O 193.00
FeSO
4·7H
2O 0.834
CuSO
4·5H
2O 0.0025
ZnSO
4 0.863
Third part: VITAMIN and other composition
HEPES 2000
Regular Insulin 5
Transferrins,iron complexes 5
Phenol red 15
D-glucose 4500
Sodium.alpha.-ketopropionate 193
Lipid mixture * 0.2% (v/v)
Primatone 1250
Reduced glutathion 0.75
Beta-mercaptoethanol 2.5
D-calcium pantothenate 4
Vitamins C 6.25
Vitamins B
64.06
Vitamins B
120.68
Choline chloride 60 9
Inositol 12.2
Folic acid 4.00
Vitamin H (Biotin) 0.02
Niacinamide 6.02
Riboflavin 0.44
VitB1 6.17
Xanthoglobulin 2.00
Thioctic Acid 0.10
Comparative Examples
Adopt the cultural method identical with embodiment 1, used substratum is the DMEM substratum that has added 5% (v/v) foetal calf serum, and cell density is 1.2 * 10 to the maximum
6Cells/mL.
Can be found by the above embodiments contrast, cultivate bhk cell in serum free medium of the present invention, the cell growth obviously is better than having the substratum of serum, and complete alternative serum is used for bhk cell and cultivates.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021106444A CN1193091C (en) | 2002-01-25 | 2002-01-25 | Serumless medium suitable for growth and maintenance of young hamster kidney cell |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021106444A CN1193091C (en) | 2002-01-25 | 2002-01-25 | Serumless medium suitable for growth and maintenance of young hamster kidney cell |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1362514A CN1362514A (en) | 2002-08-07 |
CN1193091C true CN1193091C (en) | 2005-03-16 |
Family
ID=4741177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021106444A Expired - Fee Related CN1193091C (en) | 2002-01-25 | 2002-01-25 | Serumless medium suitable for growth and maintenance of young hamster kidney cell |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1193091C (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100364527C (en) * | 2003-07-23 | 2008-01-30 | 华晨 | Composition of vitamin C and arginine and its application |
CN100432218C (en) * | 2005-01-05 | 2008-11-12 | 上海尚优生物科技有限公司 | Embryo cattle serum substitute without serum for animal cell culture |
CN100348718C (en) * | 2005-10-18 | 2007-11-14 | 中国人民解放军军事医学科学院生物工程研究所 | Culture medium without animal originating component and serum for HEK293 cell adhesion culture |
PE20161326A1 (en) * | 2014-04-10 | 2016-12-11 | Bayer Healthcare Llc | POWDER FORMULATION OF COMPOUND MEDIA AND PREPARATION METHOD OF LIQUID MEDIUM FOR CELL CULTURE |
CN104894055B (en) * | 2015-06-15 | 2018-07-17 | 成都金凯生物技术有限公司 | A kind of cell culture medium of optimization, cell culture processes and its application in preparing albumen and antibody |
CN105087460A (en) * | 2015-06-18 | 2015-11-25 | 上海源培生物科技股份有限公司 | ST cell culture medium |
CN105087461A (en) * | 2015-06-18 | 2015-11-25 | 上海源培生物科技股份有限公司 | PK cell culture medium |
CN111304169B (en) * | 2019-12-03 | 2022-03-18 | 北京亚东生物制药有限公司 | Culture medium additive, cell culture medium containing same and application thereof |
-
2002
- 2002-01-25 CN CNB021106444A patent/CN1193091C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1362514A (en) | 2002-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1908162A (en) | Serum-free culture medium of human embryo kidney (HEK) 293 cell | |
CN101418330B (en) | Non protein culture medium adapted to large-scale culture of NSO cell and production of antibody | |
CA2797356C (en) | Improved cell culture medium | |
AU2011246504B2 (en) | Improved cell culture medium | |
CN102827804B (en) | Culture medium and method suitable for the amplification culture of Vero cell microcarrier suspension | |
CN1187441C (en) | Media for culturing animal cells and process for producing protein by using same | |
CN1193091C (en) | Serumless medium suitable for growth and maintenance of young hamster kidney cell | |
CN101974481A (en) | Serum free culture medium for growing various cells derived from kidney tissue | |
CN101048511A (en) | Production of polypeptides | |
CN101052708A (en) | Serum-free cell culture medium for mammalian cells | |
EP0435911A1 (en) | Cell culture medium for enhanced cell growth, culture longevity and product expression. | |
CN101061231A (en) | Production of TNFR-Ig fusion protein | |
CN101048512A (en) | Production of anti-amyloid beta antibodies | |
CN101057635A (en) | Low-salinity autumn and winter cultivation ecological bait for litopenaeus vannamei and its preparation method | |
CN1205737A (en) | Improved immortalized human skin cell lines and novel serum-free medium useful for prodn. thereof | |
CN1696283A (en) | A serum-free medium suitable for Chinese hamster ovary cell culture | |
CN85107296A (en) | Method for preparing parenteral nutrition solution | |
CN104822821A (en) | Methods and systems for optimizing perfusion cell culture system | |
CN1024809C (en) | Method for producing useful substance using microorganism having low acetic acid-forming ability | |
CN1238498C (en) | Method for parameter control of the process for culturing serum-suspension free animal cell | |
CN101061215A (en) | Cell culture method and utilization of the same | |
CN102021139A (en) | Chinese hamster ovary culture medium as well as preparation method and application thereof | |
CN112063578B (en) | Culture medium suitable for full-suspension cell culture and preparation method and application thereof | |
US20050287666A1 (en) | Cell culture medium comprising transition metals or trace elements | |
CN1114619C (en) | Liver cancer murine monoclone antibody without endogenous immunoglobulin and its preparation and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050316 Termination date: 20140125 |